Literatur
-
1
Bateman E D, Britton M, Carrillo T, Almeida J, Wixon C.
Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment for asthma.
Clin Drug Invest.
1998;
16
193-201
-
2
Chapman K R, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M.
Salmeterol and fluticasone propionated (50/250 μg) administered via combination diskus inhaler: as effective as when given via separate diskus inhalers.
Can Respir J.
1999;
6
45-51
-
3
Fairfax A J, Spelman R.
400 MCG HFA-Beclomethasone dipropionate extrafine aerosol (QVAR™) demonstrates equivalent improvement in asthma control to 400 MCG CFC-Fluticasone propionate (Flixotide™).
Am J Respir Crit Care Med.
1999;
159
A630
-
4
June D.
Achieving the change: challenges and success in the formulation of CFC-free MDIs.
Eur Respir Rev.
1997;
7
32-34
-
5
Schultze-Werninghaus G.
Langzeittherapie des Asthma bronchiale im Erwachsenenalter.
Internist.
1999;
40
855-860
-
6
Berkovitz R B, Roberson S, Zora J, Capano D, Chen R, Lutz C, Harris A G.
Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting.
Allergy Asthma Proc.
1999;
20
167-172
-
7
Kanniess F, Richter K, Magnussen H.
Effect of inhaled ciclesonide on hypersensitivity to AMP, induced sputum and exhaled nitric oxide in subjects with bronchial asthma.
Eur Respir J.
14;
1999
289s
-
8
Fraser C M, Venter J C.
Beta-adrenergic receptors.
Am Rev Respir Dis.
1990;
141
S22-S30
-
9 Pueringer R J, Casale T B. Functional activity of lower-airway nerves. In: Busse WW, Holgate ST (Hrsg.). Asthma and Rhinitis Cambridge, Massachusetts, USA: Blackwell Science, Inc. 1995: 635-651
-
10 Laitinen L A, Laitinen A. Neural System. In: Crystal RG, West JB (Hrsg.). The Lung, scientific foundations New York: Raven Press 1991: 759-765
-
11
Casale T B, Ecklund P.
Characterization of muscarinic receptor subtypes on human peripheral lung.
J Appl Physiol.
1988;
65
594-600
-
12
Lin R Y, Pesola G R, Bakalchuk L, Morgan J P, Heyl G T, Greyberg C W, Cataquet D, Estfal R E.
Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial.
Ann Emerg Med.
1998;
31
208-213
-
13
Qureshi F, Pestian J, Davis P, Zaritsky A.
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
N Engl J Med.
1998;
339
1030-1035
-
14
Bonnert R V, Brown R C, Chapman D, Cheshire D R, Dixon J, Ince F, Kinchin E C, Lyons A J, Davis A M, Hallam C, Harpert S T, Unitt J F, Dougall I G, Jackson D M, McKechnie K, Young A, Simpson W T.
Dual D2-receptor and beta2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues.
J Med Chem.
1998;
41
4915-4917
-
15
Young A, Dougall I G, Blackham A, Jackson D M, Hallam C, Harper J W.
AR-C68397AA: The first dual D2-receptor and β2-adrenoceptor agonist.
Am J Respir Crit Care Med.
1999;
159
A522
-
16
Young A, Jackson D M, Taylor C, Ince F, Hallam C, Harpert S T.
The D2-Receptor agonist related activity of AR-C68397AA, a novel dual D2-receptor & β2-adrenoceptor agonist.
Am J Respir Crit Care Med.
1999;
159
A811
-
17
Barnes P J, Belvisi M G, Mak J C, Haddad E B, O'Connor B J.
Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease.
Life Sci.
1995;
56
853-859
-
18
Diamond J.
Role of cyclic GMP in airway smooth muscle relaxation.
Agents Actions.
1993;
43
13-26
-
19
Giembycz M A, Raeburn D.
Current concepts on mechanisms of force generation and maintenance in airways smooth muscle.
Pulm Pharmacol.
1992;
5
279-297
-
20 Rabe K F, Dent G, Magnussen H. Pharmakodynamik des Theophyllins. In: Ukena D, Keller A, Nolte D (Hrsg.). Theophyllin - Controller and Reliever bei Asthma und COPD München-Deisenhofen: Dustri-Verlag Dr. Karl Feistle 1999: 1-39
-
21 Barnes P J. Methylxanthines and phosphodiesterase inhibitors. In: Busse W, Holgate ST (Hrsg.). Asthma and rhinitis Cambridge, Massachusetts: Blackwell Science 1995: 1267-1277
-
22
Gillissen A.
Bewertung der Theophyllin-Therapie beim Asthma bronchiale.
Münch Med Wschr.
1997;
139
79-82
-
23
Nicholson C D, Challiss R AJ, Shahid M.
Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Trends Pharmacol.
1991;
12
19-27
-
24
Beasley S C, Cooper N, Gowers L, Gregory J P, Haughan A F, Hellewell P G, Macari D, Miotla J, Montana J G, Morgan T, Naylor R, Runcie K A, Tuladhar B, Warneck J B.
Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
Bioorg Med Chem Lett.
1998;
1998
2629-2634
-
25
Spina D, Landells L J, Page C P.
The role of theophylline and phosphodiesterase 4 isoenzyme inhibitors as anti-inflammatory drugs.
Clin Exp Allergy.
1998;
28
24-34
-
26
Harbinson P L, MacLeod D, Hawksworth R, O'Toole S, Sullivan P J, Heath P, Kilfeather S, Page C P, Costello J, Holgate S T, Lee T H.
The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects.
Eur Respir J.
1997;
10
1008-1014
-
27
Compton C H, Cedar E, Nieman R B, Amit O, Langley S J, Sapene M.
Ariflo™ improves pulmonary function in patients with asthma: results of a study in patients taking inhaled corticosteroids.
Am J Respir Crit Care Med.
1999a;
159
A624
-
28
Compton C H, Cedar E, Nieman R B, Amit O, Langley S J, Sapene M.
SB 207499 improves pulmonary function in patients with asthma receiving concomitant inhaled corticosteroids.
Eur Respir J.
1999b;
14
288s
-
29
Compton C H, Gubb J, Cedar E, Bakst A, Nieman R B, Amit O, Ayres J, Brambilla C.
Ariflo™ (SB 207499) a second generation, oral PDE4 inhibitor, on quality of life in patients with COPD.
Am J Respir Crit Care Med.
1999;
159
A522
-
30
Murdoch R D, Clark D, Kelley J, Cowley H, Zussman B, Benincosa L, Webber D.
Ariflo™ (SB-207499) an orally active second generation selective PDE4 inhibitor, does not interact with a variety of commonly co-administered COPD medications.
Am J Respir Crit Care Med.
1999;
159
A525
-
31
Montana J, Cooper N, Hunt H, Oxford J, Gristwood R, Lowe C, Kendall H, Buckley G, Maxey R, Warneck J, Gregory J, Gowers L, Galleway F, Naylor R, Tudhalar B, Broadley K, Danahay H.
Activity of D4418, a novel phosphodiesterase 4 (PDE4) inhibitor, effects in cellular and animal models asthma and early clinical studies.
Eur Respir J.
1999;
14
290s
-
32
Aizawa H, Inoue H, Nakano H, Matsumoto K, Yoshida M, Fukuyama S, Koto H, Hara N.
Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics.
Prostaglandins Leukot Essent Fatty Acids.
1998;
59
185-190
-
33
Baba K, Hattori T, Sakakibara A, Kobayashi T, Takagi K.
The usefulness of pranlukast of seratrodast for step-down of inhaled corticosteroid therapy in adult chronic asthma.
Am J Respir Crit Care Med.
1999;
159
A626
-
34
Ishida T, Saitoh T, Obara M, Murakami O, Hayashibara K, Watanabe S.
The effect of thromboxane A2 receptor antagonist, seratrodast in mild to moderate asthma.
Am J Respir Crit Care Med.
1999;
159
A626
-
35
Arakida Y, Suwa K, Ohga K, Yokota M, Miyata K, Yamada T.
In vitro pharmacologic profile o YM158, a new dual antagonist for LTD4 and TXA2 receptors.
J Pharmacol Exp Ther.
1998;
287
633-639
-
36
Hussein Z, Samara E, Locke C S, Orchard M A, Ringham G L, Granneman G R.
Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2-receptorantagonist AA-2414 in normal subjects: population analysis.
Clin Pharmacol Ther.
1994;
55
441-450
-
37
Hoshino M, Sim J, Shimizu K, Nakayama H, Koya A.
Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma.
J Allergy Clin Immunol.
1999;
103
1054-1061
-
38
Obase Y, Shimoda T, Matsuo N, Matsuse H, Asai S, Kohno S.
Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma.
Chest.
1999;
114
1028-1032
-
39
Magnussen H, Boerger S, Templin K, Baunack A R.
Effects of thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction.
J Allergy Clin Immunol.
1992;
89
1119-1126
-
40
Sanjar S.
Glaxo Wellcome research pipeline in chronic obstructive pulmonary disease.
Eur Respir Rev.
2000;
10
370-373
-
41
Ishizaka K, Ishizaka T.
Identification of gamma-E antibodies as a carrier of reagenic activity.
J Immunol.
1967;
99
1187
-
42
Johannson S GO, Bennick H.
Immunological studies of an atypical (mycloma) immunoglobulin.
Immunology.
1967;
13
381-394
-
43
Metzger H, Rivnay B, Henkart M, Kanner B, Kinet J P, Perez-Montort R.
Analysis of the structure and function of the receptor for immunoglobulin E.
Mol Immunol.
1984;
21
1167-1173
-
44
Semper A E, Hartley J A.
Dendritic cells in the lung - what is their relevance to asthma.
Clin Exp Allergy.
1996;
26
485-490
-
45
Bozelka B E, McCants M L, Salvaggio J E, Lehrer S B.
IgE isotype suppression in anti-ε treated mice.
Immunology.
1982;
46
527-532
-
46
Marone G, Spadaro G, Palumbo C, Condorelli G.
The anti-IgE/anti-FcεRIα autoantibody network in allergic and autoimmune diseases.
Clin Exp Allergol.
29;
1999
17-27
-
47
Shields R L, Whether W R, Zioncheck K, O'Connell L, Fendly B, Presta L G, Thomas D, Saban R, Jardieu P.
Inhibition of allergic reactions with antibodies to IgE.
Int Arch Allergy Immunol.
1995;
107
308-312
-
48
Boulet L P, Chapman K R, Coté J, Kalra S, Bhagat R, Swystun V A, Laviolette M, Cleland L D, Deschesnes F, Su J Q, DeVault A, Fick Jr R B, Cockroft W.
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.
Am J Respir Crit Care Med.
1997;
155
1835-1840
-
49
Casale T B, Bernstein I L, Busse W W, LaForce C F, Tinkelman D G, Stoltz R R, Dockhorn R J, Reimann J, Su J Q, Fick R B, Adelman D C.
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.
J Allergy Clin Immunol.
1997;
100
110-121
-
50
Fahy J V, Fleming E, Wong H H, Liu J T, Su J Q, Reimann J, Fick Jr R B, BBoushey H A.
The effect of an anti-IgE monoclonal antibody on the early- and late phase response to allergen inhalation in asthmatic subjects.
Am J Respir Crit Care Med.
1997;
155
1828-1834
-
51
Fox J A, Hotaling T E, Struble C, Ruppel J, Bates D J, Schoenhoff M B.
Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys.
J Pharmacol Exp Ther.
1996;
279
1000-1008
-
52
Metzger H, Fick R B.
Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (rhuMAbE25).
J Allergy Clin Immunol.
1998;
101
S231
-
53
Demoly P, Bousquet J.
Anti-IgE therapy for asthma.
Am J Respir Crit Care Med.
1997;
155
1825-1827
-
54 Howarth P H, Bradding P, Quint D, Redington A E, Holgate S T. Cytokines and airway inflammation. In: Chignard M, Pretolani M, Renesto P, Vargaftig BB (Hrsg.). Cells and cytokines in lung inflammation New York: New York Academy of Sciences 1994: 69-82
-
55 Zangrilli J G, Peters S P. Cytokines in allergic airway disease. In: Busse W, Holgate ST (Hrsg.). Asthma and rhinitis Cambridge: Blackwell Science Inc. 1999: 426-436
-
56
Pauwels R A, Brusselle G G, Tournoy K G, Lambrecht B N.
Cytokines and their receptors as therapeutic targets in asthma.
Clin Exp Allergol.
1998;
28
1-5
-
57
Park C S, Choi Y S, Ki S H, Moon S H, Jeong S W, Uh S T, Kim Y H.
Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways.
Eur Respir J.
1998;
12
872-878
-
58
Danzig M, Cuss F.
Inhibition of interleukin-5 with aa monoclonal antibody attenuates allergic inflammation.
Allergy.
1997;
52
787-794
-
59
Ohnishi T, Kita H, Weiler D, Sur S, Sedgwick J, Calhoun W J, Busse W W, Abrams J S, Gleich G J.
IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction.
Am Rev Respir Dis.
1993;
147
901-907
-
60
Ohnishi T, Sur S, Collins D S, Fish J E, Gleich G J, Peters S P.
Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge.
J Allergy Clin Immunol.
1993;
92
607-615
-
61
Kaminuma O, Mori A, Ogawa K, Kakata A, Kikkawa H, Naito K, Suko M, Okudaira H.
Successful transfer of late phase eosinophil infiltration in the lung by infusion of helper T cells clones.
Am J Respir Cell Mol Biol.
1997;
16
448-454
-
62
Leckie M J, Brinke ten A, Lordan J, Kahn J, Diamant Z, Walls C M, Cowley H, Webber D, Hansel T T, Djukanovic R, Sterk P J, Holgate S T, Barnes P J.
A humanized anti-IL-5 monoclonal antibody: initial single dose safety and activity in patients with asthma.
Am J Respir Crit Care Med.
1999;
159
A624
-
63
Cieslewicz G, Tomkinson A, Adler A, Duez C, Schwarze J, Takeda K, Larson K A, Lee J J, Irvin C G, Gelfand E W.
The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration.
J Clin Invest.
1999;
104
301-308
-
64
Weltman J K, Karim A S.
Interleukin-5: a proeosinophil cytokine mediator of inflammation in asthma and a target for antisense therapy.
Allergy Asthma Proc.
1998;
19
257-261
-
65
Molet S, Ramos-Barbon D, Martin J G, Hamid Q.
Adoptively transferred late allergic response is inhibited by IL-4, but not IL-5, antisense oligonucleotide.
J Allergy Clin Immunol.
1999;
104
205-214
-
66
Zhou C Y, Crocker I C, Koenig G, Romero F A, Townley R G.
Anti-interleukin-4 inhibits immunoglobulin E production in a murine model of atopic asthma.
J Asthma.
1997;
34
195-201
-
67
Harris P, Lindell D, Fitch N, Gundel R.
The IL-4 receptor antagonist (BAY 16-9996) reverses airway hyperresponsiveness in a primate model of asthma.
Am J Respir Crit Care Med.
1999;
159
A230
-
68
Hogan S P, Foster P S, Tan X, Ramsey A J.
Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity.
Eur J Immunol.
1998;
28
413-423
-
69
Renz H, Enssle K, Lauffer L, Kurrle R, Gelfand E W.
Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor.
Int Arch Allergy Appl Immunol.
1995;
106
46-54
-
70
Renz H, Bradley A, Enssle K, Loader J, Larsen G L, Gelfand E W.
Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor.
Int Arch Allergy Appl Immunol.
1996;
109
167-176
-
71
Borish L C, Nelson H S, Bensch G, Corren J, Busse W, Whitmore J, Agosti J.
Phase I/II study of soluble interleukin-4 receptor (IL-4R) in adults with moderate asthma.
Eur Respir J.
1999;
14
288s
-
72
Corrigan C J, Kay A B.
CD4 T lymphocyte activation in acute severe asthma.
Int Arch Allergy Appl Immunol.
1991;
94
270-271
-
73
Nagase T, Fukuchi Y, Matsuse T, Sudo E, Matsui H, Orimo H.
Antagonism of ICAM-1 attenuates airway and tissue response to antigen in sensitized rats.
Am J Respir Crit Care Med.
1995;
151
1244-1249
-
74
Rabb H A, Olivenstein R, Issekutz T B, Renzi P M, Martin J G.
The role of leukocyte adhesion molecules VLA-4, LFA-1, and Mac-1 in allergic airway responses in the rat.
Am J Respir Crit Care Med.
1994;
149
1186-1191
-
75
Sagara H, Matsuda H, Wada N, Yagita H, Fukuda T, Okumura K, Makino S, Ra C.
A monoclonal antibody against very late activation antigen-4 inhibits eosinophil accumulation and late asthmatic response in a guinea pig model of asthma.
Int Arch Allergy Appl Immunol.
1997;
112
287-294
-
76
Stamatiou P B, Hamid Q, Taha R, Yu W, Issekutz T B, Rokach J, Khanapure S P, Powell W S.
5-Oxo-6,6,11,14-eicosatetraeoic acid stimulates eosinophil infiltration into rat lungs in an integrin-dependent fashion.
Am J Respir Crit Care Med.
1999;
159
A33
-
77
Tomkinson A, Cieslewicz G, Duez C, Lee J J, Gelfand E W.
Lung eosinophilia and relationship to airway hyperresponsiveness (AHR) in mice: effect of IL-5 and VLA-4 antibody.
Am J Respir Crit Care Med.
1999;
159
A228
-
78 Kroegel C, Herzog V, Förster M, Braun R. Pathogenetische Grundlagen des Asthma bronchiale. In: Kroegel C (Hrsg.). Asthma bronchiale Stuttgart: Thieme 1998: 13-51
Prof. Dr. med A Gillissen
Medizinische Klinik und Poliklinik II Rheinische Friedrich-Wilhelms-Universität Bonn
Sigmund-Freud-Str. 25 53105 Bonn
eMail: E-mail: adrian.gillissen@meb.uni-bonn.de
